Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

AstraZeneca, Ironwood start Phase III IBS trial in China
October 2013
SHARING OPTIONS:

CAMBRIDGE, Mass.AstraZeneca Pharmaceuticals Co. Ltd. and Ironwood Pharmaceuticals Inc. have initiated a Phase III clinical trial in China to evaluate linaclotide for the treatment of adults with irritable bowel syndrome with constipation (IBS-C). The drug is approved to treat adults with IBS-C or chronic idiopathic constipation in the United States and adults with moderate to severe IBS-C in the European Union. The companies expect top-line data to be available in the first half of 2015, and, should it gain approval, expect linaclotide to be on the market in China in 2017. AstraZeneca and Ironwood formed a collaboration in October 2012 to develop and commercialize linaclotide in China, with AstraZeneca assuming primary responsibility for local operation execution.

Back



PAGE UTILITIES


CONTACT US
DDNEWS
1000 N West Street, Suite 1200,
Wilmington, Delaware, 19801
Ph: 888-781-0328 |  Fax: 705-528-0270
 
© Copyright 2020 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.